HJLI Insider Trading Activity and SEC Form 4 Filings
HJLI insider trading summary
No open-market insider purchases or sales of Hancock Jaffe Laboratories, Inc. (HJLI) have been reported on SEC Form 4 in the past 12 months.
Latest HJLI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 25, 2021 | Matthew Jenusaitis | Director | Buy | $10K (1,300 @ $7.70) |
| Jun 16, 2021 | Robert Gray | Director | Buy | $13K (2,000 @ $6.25) |
| May 21, 2021 | Marc H. Glickman | SVP & Chief Medical Officer | Buy | $9K (1,600 @ $5.90) |
| May 18, 2021 | Robert Andrew Berman | Chief Executive Officer | Buy | $16K (3,000 @ $5.47) |
| May 17, 2021 | Francis Duhay | Director | Buy | $51K (9,492 @ $5.33) |
| Aug 21, 2020 | Biodyne Holding, S.A. | Insider | Sell | $29K (75,000 @ $0.38) |
| Aug 20, 2020 | Biodyne Holding, S.A. | Insider | Sell | $20K (75,000 @ $0.27) |
| Aug 19, 2020 | Biodyne Holding, S.A. | Insider | Sell | $15K (50,000 @ $0.30) |
| Aug 18, 2020 | Biodyne Holding, S.A. | Insider | Sell | $17K (50,000 @ $0.34) |
| Aug 14, 2020 | Biodyne Holding, S.A. | Insider | Sell | $16K (50,000 @ $0.31) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.